David Stickler, MD
Neurology · North Charleston, SCNPI 1699711945
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 11.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,173 and has fallen 89.4% since, to $124 in 2025.
Across 114 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$242
- EDW Pharma, Inc.$206
- Amgen$167
- UCB, Inc.$127
- AstraZeneca$108
- Sanofi$108
- plus $1K from 29 others
Across 210 payments — averaging $5729.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$359K
- AbbVie$290K
- Adamas Pharmaceuticals, Inc.$139K
- Amgen$94K
- AstraZeneca$81K
- Lexicon Pharmaceuticals, Inc.$71K
- plus $170K from 5 others
What the payments were for
- Speaking & faculty fees$131%
- Food & beverage$2,16299%
- Education$131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 8 | $242 |
| EDW Pharma, Inc. | 1 | $206 |
| Amgen(2 entities) | 9 | $167 |
| UCB, Inc. | 9 | $127 |
| AstraZeneca | 6 | $108 |
| Sanofi | 6 | $108 |
| Biohaven Pharmaceuticals, Inc. | 4 | $88 |
| Acadia Pharmaceuticals Inc | 6 | $81 |
| Tanabe Pharma America, Inc. | 5 | $71 |
| Bausch Health US, LLC | 4 | $69 |
| Alnylam Pharmaceuticals Inc. | 3 | $69 |
| CSL Behring | 3 | $68 |
| Lilly USA, LLC | 5 | $64 |
| Genentech USA, Inc. | 5 | $62 |
| Supernus Pharmaceuticals, Inc. | 4 | $60 |
| Novartis | 4 | $55 |
| Natus Medical Incorporated | 1 | $53 |
| Bristol Myers Squibb | 3 | $52 |
| Upsher-smith Laboratories LLC | 3 | $50 |
| Johnson & Johnson | 3 | $49 |
| Amneal Pharmaceuticals LLC | 3 | $43 |
| GE HealthCare | 3 | $39 |
| SK Life Science, Inc. | 2 | $34 |
| Lundbeck LLC | 1 | $32 |
| Biogen | 2 | $31 |
| Collegium Pharmaceutical, Inc. | 2 | $30 |
| Promius Pharma LLC | 1 | $24 |
| Akcea Therapeutics, Inc. | 1 | $15 |
| Grifols USA, LLC | 1 | $15 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $13 |
| Hospira, Inc. | 1 | $13 |
| Acorda Therapeutics, Inc | 1 | $13 |
| MDD US Operations, LLC | 1 | $13 |
| Eisai Inc. | 1 | $13 |
| Boston Scientific | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,188 in reported general payments places this provider in the 60th percentile of 270 neurology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 52 | $397,106 |
| BriviactBrivaracetam | 17 | $39,019 |
| GlatopaGlatiramer Acetate | 14 | $37,632 |
| QuliptaAtogepant | 22 | $26,337 |
| Aimovig AutoinjectorErenumab-Aooe | 24 | $21,728 |
| Pyridostigmine Bromide | 58 | $4,782 |
| Lacosamide | 21 | $4,045 |
| Oxcarbazepine | 22 | $2,315 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 76 | $2,313 |
| Mycophenolate Mofetil | 32 | $2,183 |
| Scopolamine | 24 | $2,091 |
| Azathioprine | 32 | $2,090 |
| DilantinPhenytoin Sodium Extended | 12 | $1,942 |
| Memantine Hcl | 31 | $1,763 |
| Levetiracetam | 44 | $1,142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact | $127 | $39,01917 claims |
| AbbVieQulipta | $242 | $26,33722 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil | $43 | $6,96590 claims |
| Upsher-smith Laboratories LLCTopiramate | $50 | $60539 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 270 neurology providers in South Carolina.
Other neurology in North Charleston
- John BakerSumter$779K
- Robert CarlileSummerville$428K
- Mary HughesGreenville$404K
- Jose CardenasAiken$216K
- Fredy RevillaGreenville$208K
- Robert AdamsCharleston$204K
- Thomas HughesMt. Pleasant$102K
- Kathleen WoschkolupGreenville$97K
- Sarah BreevoortCharleston$90K
- David HammettColumbia$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.